Rep. Maria Elvira Buys Shares of Biogen Inc. (BIIB)
Maria Elvira, a House member, recently bought shares of Biogen Inc.
Financial Disclosure Report
Clerk of the House of Representatives • Legislative Resource Center • B81 Cannon Building • Washington, DC 20515
Filer Information
- Name:
- Rep. Maria Elvira (R)
- Status:
- Member — House
Filing Information
- Filing Type:
- Periodic Transaction Report
- Filing Year:
- 2026
- Filing Date:
- Jun 9, 2026
Schedule B: Transactions
| Asset | Transaction | Date | Amount |
|---|---|---|---|
| Biogen Inc. ($BIIB) | Buy | May 12, 2026 | $1,001 - $15,000 |
Key Points
- Maria Elvira purchased Biogen Inc. shares valued between $1,001 and $15,000, according to a report filed on June 9, 2026.
- Biogen's stock trades around $199.96 with a market cap of $29.5 billion and a P/E ratio of 21.5.
- Analysts like Needham and RBC Capital have set price targets as high as $255, with a consensus recommendation to buy.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
Maria Elvira, a member of the House, purchased shares of Biogen Inc. (NasdaqGS: BIIB) valued between $1,001 and $15,000. This transaction was reported on June 9, 2026, under the STOCK Act, which requires members of Congress to disclose their trades.
Maria Elvira vs. the S&P 500
Hypothetical, simulated performance of disclosed positions vs. the S&P 500. Not realized profit and not investment advice. Past performance does not indicate future results. Details.
Biogen Inc. Stock Down 9.1%
Shares of Biogen Inc. are trading around $199.96. The company has a market cap of approximately $29.5 billion and a P/E ratio of 21.5, with a forward P/E of 12.0. Biogen's beta is quite low at 0.177, indicating lower volatility compared to the market. The stock's 52-week range is between $121.05 and $205.97, with a 50-day moving average of $188.47 and a 200-day moving average of $173.14.
$BIIB stock price
Daily closing prices, year to date. Not investment advice.
Recent Earnings
Biogen reported revenue of about $9.94 billion, with a revenue growth of 1.9%. The company achieved a net margin of 13.8% and a return on equity of 7.7%. Biogen's next earnings report is expected on April 29, 2026.
Earnings drift grade
Outlook vs expectations on the last report — not price action.
-
Forward outlook
5 target raises vs 1 cuts.
-
EPS & revenue
EPS beat estimates by 26.3%. Revenue beat estimates by 7.7%.
-
Profit surprise
EBITDA missed by 7 percent. Operating income missed by 14 percent.
-
Pre-earnings setup
Expectations were about average.
-
Analyst signal
5 target raises, 1 target cut.
-
Earnings quality
Gross margin down 2.9 points. Operating margin down 14.1 points. Positive free cash flow.
Earnings Call Summary
Biogen had a very strong first quarter with growth products generating 851 million dollars, up 12 percent year-over-year. LEQEMBI sales surged 74 percent to 168 million dollars, benefiting from expansion in the U.S., Japan, and China. The company highlighted real-world evidence showing nearly 80 percent of LEQEMBI patients remain on therapy at 18 months, supporting the durability of treatment. High-dose SPINRAZA launched successfully with 20 percent of U.S. patients already switching, and the company is preparing for multiple pipeline readouts starting this year, including data on tau-targeting drug BIIB080 and lupus candidate Litifilimab.
Guidance Biogen reaffirmed its full-year guidance, confident in underlying business strength. The company expects to close the Apellis acquisition in the second quarter and will provide combined guidance after close. Management noted about 600 million dollars of contract manufacturing revenue expected this year, roughly two-thirds in the first half. They anticipate the acquisition will be accretive to earnings per share in 2027.
Slightly positive report. The quarter was acceptable, but the forward setup is not strong.
Analysts Set New Price Targets
On June 8, 2026, Needham upgraded Biogen to a 'buy' rating, setting a price target of $255. RBC Capital maintained its 'buy' rating with a target of $227 on May 27, 2026. Piper Sandler reiterated its 'buy' rating with a $225 target on May 15, 2026. The consensus among 30 analysts is a 'buy' rating with a mean price target of $220.63.
Insider Buying and Selling at Biogen Inc.
Recent insider activity includes Menelas Pangalos buying 2,370 shares on June 9, 2026. Other insiders like Eric Rowinsky and Stephen Sherwin also bought shares on the same day.
About Biogen Inc.
Biogen Inc. is a healthcare company based in Cambridge, Massachusetts, specializing in therapies for neurological and neurodegenerative diseases. Led by CEO Christopher A. Viehbacher, the company employs around 7,500 people. Biogen's portfolio includes treatments for multiple sclerosis, spinal muscular atrophy, and Alzheimer's disease, among others.
Bottom Line
Maria Elvira's purchase of Biogen shares highlights the interest in the company's potential in the healthcare sector. With a solid market cap and a range of treatments, Biogen remains a significant player in its industry. Analyst recommendations and insider activities provide additional insights into the stock's outlook.
Get Biogen Inc. alerts
New 13F filings, insider trades, and analyst moves on $BIIB, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.